ESN Cleer reposted this
I’m #hiring. Know anyone who might be interested? 👋😊
This content isn’t available here
Access this content and more in the LinkedIn app
About us
ESN Cleer is committed to transforming the way we combat specific segments of Cardiomyopathy with its focus on repurposed drugs of orphan indications (rare diseases without specific drug treatments). Such detrimental diseases are some of the most significant causes of Heart Failure—an ailment that heavily impact on a large spectrum of the CVD population. Such diseases or syndromes carry a high mortality risk, but it also profoundly degrades the quality of life for those affected, thus underlining the importance of ESN Cleer's mission.
- Website
-
http://www.cleer.com.au
External link for ESN Cleer
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Melbourne , VIC
- Type
- Public Company
- Founded
- 2018
- Specialties
- Cardiovascular Disease, heartdisease, biotech, and cardiomyopathy
Locations
-
Primary
Get directions
Melbourne , VIC 3000, AU
Employees at ESN Cleer
-
Matt McNamara
-
Chris Pattas
CEO Advisor. Board Director. Chair of Finance, Audit, Investment & Risk (FAIR) committee. Investor. Expertise in growing revenue, leveraging…
-
Andrew J. Stewart Coats
Experienced Medical and Commercial Entrepreneur
-
Gustav de Bruin
COO / Program director - MAICD, MBA(hons), B.Tech, M.IT
Updates
-
We thank all our stakeholders for their ongoing support throughout 2023. Without you this journey wouldn't be possible. We wish you a Merry Christmas and a Happy New Year! Sincerely ESN Cleer Team #pharmaceuticals #medical #entrepreneur #marketing #funding #investment #management #business #machinelearning #medicine #entrepreneurs #entrepreneurship #innovation #pharma #medtech #investing #technology #medicaldevices #health #biotechnology #fundraising #healthcare #startups #branding #venturecapital
-
🚀 Exciting Developments in the Pharma Landscape! 🌐 As the pharmaceutical industry navigates the dynamic terrain, two significant forces are shaping its future - the Patent Cliff and the groundbreaking Inflation Reduction Act 2022 (IRA). Patent Cliff Alert! 🚨 Major drugmakers brace for impact as market exclusivity dwindles with impending patent expirations, paving the way for generic competitors. The industry anticipates a colossal loss of over US$200 billion in annual revenue by 2030. Game-Changer: Inflation Reduction Act 2022! 💼 Envisioning a more affordable healthcare future, the IRA is set to revolutionize drug pricing. Negotiations commenced in 2023, with implementation slated for 2026. The first wave targets 10 drugs, focusing on high-expenditure, non-generic, and long-standing market presence. Projections indicate a potential reduction of drugmakers' revenue by a staggering US$ 450 billion by 2032. Shift in R&D Strategies! 🧪 The industry witnesses a paradigm shift in internal R&D, with prescription drug sales seeing a drop below 40% in 2023. As pharmaceutical giants adapt to this change, strategic planning becomes pivotal for sustained success. Introducing ESNtx005: A Beacon of Innovation! 🌟 Amidst challenges, emerges ESNtx005, a novel drug targeting orphan indications in Restrictive Cardiomyopathy. With a fresh patent, market exclusivity, and exemption from the IRA, it stands as a beacon of innovation. Boasting 20 years of patent protection, low R&D costs, and a myriad of incentives, including the Orphan Drug Tax Credit, clinical research subsidies, and fast-track approval opportunities, ESNtx005 is a testament to the industry's resilience. Orphan Drug Market Soars! 📈 The global orphan drug market is set to soar to unprecedented heights, projected to reach US$ 368+ billion by 2030 with an impressive 11.6% CAGR. M&A activity in 2023 alone surpassed US$ 170 billion, reflecting a strategic focus on orphan drugs. Q3 2023 witnessed 34 orphan drug acquisitions valued at a staggering US$ 13.5+ billion. As we navigate the ever-evolving pharmaceutical landscape, these transformative trends underscore the industry's commitment to innovation, affordability, and improved patient outcomes. Stay tuned for more groundbreaking developments! 💊✨ #PharmaInnovation #HealthcareRevolution #DrugDiscovery #BiotechAdvancements #Pharmaceuticals #Medical #Entrepreneur #Marketing #Funding #Investment #Management #Business #MachineLearning #Medicine #Entrepreneurs #Entrepreneurship #Innovation #Pharma #MedTech #Investing #Technology #MedicalDevices #Health #Biotechnology #Fundraising #Healthcare #Startups #Branding #VentureCapital
-
Orphan Drug Designation's Ripple Effect. #pharmaceuticals #medical #entrepreneur #marketing #funding #investment #management #business #machinelearning #medicine #entrepreneurs #entrepreneurship #innovation #pharma #medtech #investing #technology #medicaldevices #health #biotechnology #fundraising #healthcare #startups #branding #venturecapital
Orphan Drug Designation's Ripple Effect.
ODD's Ripple Effect: ASX Biotech Prices, FDA Incentives and Big Pharma
Matthew Baker on LinkedIn
-
Our CEO, Leopoldt de Bruin, leading the way in a Heart Healthy lifestyle making a small step towards a big difference in HEALTH! #health #esncleer #leopoldtdebruin #calvindebruin #tennis #ygtc #rogerfederer
Health starts from making smart healthy lifestyle choices. Sport is one major factor that helps reduce the risk of Heart Disease and a whole host of other diabolical diseases. Tennis 🎾 I LOVE TENNIS!! I can claim that one thing Roger Federer and I have in common is we both have a South African parent(s). 😁 #samgroth #leyton #rogerfederer #yarraglen #calvindebruin #southafrica #saffa #ausie #letsgo #ygtc
-
-
Global Biotech's poised for growth. #investing #venturecapital #biotech #entrepreneurship #cleer #esncleer #cleerhealth #capitalcell
1. Biotech investment fund reckons sector is poised for growth but Australia not ready to capitalise on growth 2. Per capita, Australia leads biomedical research productivity but invests substantially less in commercialisation 3. Several factors driving ASX biotech downturn in 2023 beyond economic uncertainty and global geopolitical tensions #investing #venturecapital #biotech #entrepreneurship #cleer #esncleer #cleerhealth #capitalcell
Global biotech sector set to boom but where are Aussie investors? - Stockhead
https://stockhead.com.au
-
Did you know heart disease kills ten million people every year? Did you know there are several disease-clusters within the heart disease classification without a guideline approved treatment? One such cluster is restrictive cardiomyopathy. ESN Cleer developed a drug targeting specific cardiomyopathies where no treatments exist. We are hosting an introductory webinar and would like to invite you to join us on the 29th of November at 7pm (AEST) with our host Capital Cell based in Europe. You are welcome to come listen to what we do and our future exciting developments and investment opportunities for those who are interested in making a difference in cardiovascular disease the number one killer in the world! Join us for our introduction webinar via the link provided below or click the link in our Bio or feel free to contact us via our website if you would like us to send you a direct link: https://lnkd.in/g4HYjMhU We look forward to seeing you there! The ESN Cleer Team 🫀 #capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments #personalisedmedicine #biotech #capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #strokeawareness #blood #diagnosticstreatments #personalisedmedicine #BiotechInvestment #PharmaPartnerships #OrphanDrug #CardiomyopathyResearch #HealthInnovation #BioTechDevelopment
-
-
Did you know? 80% of the top 10 Pharmaceutical companies are increasing their orphan drug portfolios over the next 3 years towards 35% on average for their respective drug portfolios? With Johnson and Johnson (39%), Vertex (98%), and Astrazeneca (36%) leading the way according to the Evaluate industry report. The ESN Cleer Team 🫀 #capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments #personalisedmedicine #BiotechInvestment #PharmaPartnerships #OrphanDrug #CardiomyopathyResearch #HealthInnovation #BioTechDevelopment https://lnkd.in/gJbZjvZa
Evaluate Orphan Drug Report.pdf
info.evaluate.com
-
Many believe they’re healthy, but restrictive cardiomyopathy silently progresses. By the time symptoms appear, it may be in early heart failure. This global issue lacks a specific treatment. Post-heart failure, survival rates drop to 10% over a decade, resulting in 10 million annual deaths. ESN Cleer developed a groundbreaking drug for this condition. ESN Cleer aims to ease the significant burden imposed by restrictive cardiomyopathy on individuals, families, governments, and healthcare systems. Reserve your investment at: https://lnkd.in/grJKCus7 #capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments #personalisedmedicine #biotech